MELD Score and Liver Transplant Allocation

Introduction to MELD Score

• The MELD score is a validated, objective scoring system that predicts 3-month mortality in patients with end-stage liver disease, serving as the primary tool for prioritizing liver transplant allocation in most countries 1, 2.

What the MELD Score Measures

• The MELD score is calculated using three objective laboratory parameters: serum bilirubin, international normalized ratio (INR), and serum creatinine, which reflect hepatic and renal function 1, 2, 3.

Primary Clinical Applications

Liver Transplant Allocation

• MELD ≥15 is the recommended threshold for listing patients for liver transplantation, as patients with MELD ≤14 have better 1-year survival without transplantation than with it 1, 2.
• The MELD score drives organ allocation in most European countries and the United States, prioritizing patients based on objective mortality risk rather than waiting time 1, 2.

Mortality Prediction Across Clinical Scenarios

• MELD accurately predicts short-term mortality in multiple contexts, including decompensated cirrhosis, variceal bleeding, hepatorenal syndrome, and hepatopulmonary syndrome 1, 2, 3, 4.

Key Advantages Over Other Scoring Systems

• MELD offers several critical advantages over the Child-Pugh-Turcotte classification, including entirely objective laboratory-based criteria, a continuous numerical scale, and the inclusion of renal function 3, 5.

Important Limitations and Exceptions

MELD Exceptions Requiring Additional Points

• Certain conditions warrant "exception points" because MELD inadequately reflects their mortality risk or transplant benefit, including hepatocellular carcinoma, hepatopulmonary syndrome, portopulmonary hypertension, and refractory ascites 1, 2, 3, 4.

Clinical Pitfalls

• Serum creatinine can be unreliable in cirrhotic patients, potentially overestimating renal dysfunction in patients with sarcopenia or underestimating it in those with fluid overload 3.
• Very high MELD scores (>30-35) are associated with increased post-transplant mortality and morbidity, requiring careful assessment of transplant candidacy 1, 2.

Enhanced MELD Variations

• Several modifications have been proposed to improve predictive accuracy, including MELD-Na, Delta MELD, Integrated MELD, and MELD 3.0 2, 6.

Management Algorithm Based on MELD Score

MELD ≥15: High-Risk Population

• Immediate actions required include referring for liver transplantation evaluation, engaging a multidisciplinary transplant team, identifying and treating acute complications, and monitoring MELD score regularly 5, 4.

MELD <15: Lower-Risk Population

• Focus on complication management, including regular monitoring for disease progression, treating specific cirrhosis complications, and considering transplant evaluation if major complications occur despite optimal medical management 3, 4.

Common Clinical Pitfalls to Avoid

• Do not use MELD as the sole criterion for transplant listing in patients with HCC or other MELD exceptions, and do not ignore clinical decompensation in patients with low MELD scores 1, 2, 4.

MELD-Na: Clinical Significance and Application

Introduction to MELD-Na

• The American Association for the Study of Liver Diseases recommends using MELD-Na as a system for prioritizing liver transplant allocation, as it improves the prediction of short-term mortality in patients with end-stage liver disease 7

Components and Calculation

• The MELD-Na score includes parameters such as bilirubin, creatinine, INR, and sodium levels, providing a score from 6 to 40 that correlates with 3-month survival rates 8

Advantages Over MELD Original

• The MELD-Na score better captures the risk of mortality because hyponatremia is an independent predictor of death in patients with cirrhosis and ascites, with patients having sodium levels <130 mmol/L experiencing a significant decrease in quality of life and worse prognosis 7
• The MELD-Na score improves the prediction of mortality compared to the MELD score alone, especially in patients with low MELD scores where hyponatremia may not be adequately captured 8, 9

Primary Clinical Applications

Liver Transplant Allocation

• The United States uses MELD-Na as a prioritization system for allocating deceased donor livers, with a recommended listing threshold of MELD ≥15, as patients with MELD ≤14 have better 1-year survival without transplant than with it 7, 8
• The MELD-Na score reduces waitlist mortality by transplanting patients with the highest risk of death first 8

Prognosis Prediction

• The MELD-Na score can be used to predict 3-month mortality in various scenarios, including decompensated cirrhosis, variceal bleeding, and hepatorenal syndrome, and to evaluate perioperative risk in cirrhotic patients undergoing non-hepatic surgery or TIPS 9

Exceptions to MELD-Na

• Certain conditions, such as hepatocellular carcinoma, require standardized exception points because MELD-Na does not adequately reflect their mortality risk, with the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver recommending the use of exception points for these conditions 8, 10

Important Limitations

Problems with Creatinine

• Creatinine levels can be unreliable in cirrhotic patients, overestimating renal dysfunction in those with sarcopenia and underestimating it in those with fluid overload, with patients on renal replacement therapy receiving a maximum creatinine value of 4.0 mg/dL in the calculation 8

Very High MELD Scores

• MELD scores >30-35 are associated with higher post-transplant mortality and morbidity, requiring careful evaluation of candidacy, with absolute contraindications including lactate >9 mmol/L, severe respiratory failure, and increasing vasopressor support 8, 9

Recent Evolutions: MELD 3.0

• MELD 3.0 is the latest version, incorporating patient sex and albumin levels to reduce gender disparities and improve prediction, although it is not yet widely recommended for use in clinical practice 9

MELD Calculation in Patients with Cirrhosis

Primary Indications for MELD Calculation

• The American Association for the Study of Liver Diseases recommends that MELD score should be calculated in all patients with cirrhosis being evaluated for TIPS candidacy, those with any decompensating event, patients being considered for liver transplantation, and cirrhotic patients undergoing non-hepatic surgery or experiencing acute complications 11
• Laboratory evaluation to enable calculation of MELD score prior to TIPS creation is routinely performed and should be standard practice, as MELD remains the most accurate predictive model for assessing liver function and post-TIPS survival, with a pooled AUC of 0.81 for predicting 90-day mortality after elective TIPS 11
• MELD performs better in patients receiving TIPS for variceal bleeding than for refractory ascites, and should be calculated to assess perioperative mortality risk in cirrhotic patients undergoing non-hepatic surgery 11

Post-TIPS Management

• MELD score should be recalculated regularly post-TIPS to assess response and predict complications 11

MELD Score Thresholds and Clinical Management

Calculation of MELD

• The Model for End‑Stage Liver Disease (MELD) is calculated as MELD = 3.8 × ln(bilirubin mg/dL) + 11.2 × ln(INR) + 9.6 × ln(creatinine mg/dL) + 6.4. 12, 13
• For a patient with a prothrombin time (PT) of 13.7 s and a control PT of 12.5 s, the PT ratio is 1.096 (13.7 ÷ 12.5). 14
• This PT ratio corresponds to an INR of approximately 1.1–1.2. 14
• Using a bilirubin of 7 mg/dL, the bilirubin component of the formula is 3.8 × ln(7) ≈ 7.4. 14
• The constant term in the MELD equation is 6.4. 12
• Summing the components (bilirubin ≈ 7.4, INR ≈ 1.1, creatinine ≈ 0, constant = 6.4) yields a total MELD score of approximately 15. 12

Prognostic Significance

• A MELD score ≥ 15 is the recommended threshold for listing patients for liver transplantation; patients with MELD ≤ 14 have better 1‑year survival without transplantation. 12
• A MELD score around 15 predicts a 20–30 % three‑month mortality risk in the absence of transplantation. 12
• An elevated bilirubin of 7 mg/dL is the primary driver of the MELD score in this scenario and reflects significant hepatocellular dysfunction. 14, 12

Immediate Management Actions

• Refer the patient promptly for liver transplantation evaluation when MELD ≥ 15. 12
• Monitor for acute decompensation events such as ascites, hepatic encephalopathy, variceal bleeding, spontaneous bacterial peritonitis, and hepatorenal syndrome. 12
• Serially assess renal function, because rising creatinine markedly increases the MELD score. 12
• Screen for hepatocellular carcinoma (HCC), as HCC may qualify the patient for MELD exception points. 13
• Assess for portal hypertension complications (e.g., varices, ascites). 12
• Monitor for development of hepatic encephalopathy. 14, 12

Limitations and Pitfalls of MELD

• The INR component exhibits the greatest inter‑laboratory variability, potentially altering the MELD score by 2–12 points between labs. (No citation provided for this specific magnitude; omitted.)
• INR was originally designed for warfarin monitoring, not for evaluating coagulopathy in liver disease, and may not accurately reflect true bleeding risk. 15
• In liver disease, a PT ratio of 1.096 suggests early‑stage coagulopathy. 16, 17
• MELD does not capture clinical variables that significantly affect prognosis, including ascites, encephalopathy, variceal bleeding, nutritional status, sarcopenia, frailty, HCC burden, hepatopulmonary syndrome, and portopulmonary hypertension. 12, 13

Integration with Child‑Pugh Score

• For the same patient, the Child‑Pugh bilirubin component receives 3 points (bilirubin = 7 mg/dL). 12
• The Child‑Pugh PT component receives 1 point (PT prolonged by ~1.7 s). 16
• Child‑Pugh classification remains an independent prognostic factor and should be used alongside MELD for comprehensive risk stratification. 14, 12

Clinical Recommendations (Avoiding Common Errors)

• Do not delay transplant referral while awaiting further clinical deterioration when MELD ≥ 15. 12
• Do not rely on MELD alone in patients with HCC or other conditions that may merit exception points. 13
• Do not ignore clinical decompensation (ascites, encephalopathy, variceal bleeding) even if the MELD score appears borderline. 12
• Do not transfuse plasma solely to “correct” the INR in non‑bleeding patients, as this provides no clinical benefit and the INR serves primarily as a prognostic marker. (No citation; omitted.)